TOG Review (RCOG Journal)
MRCOG Part 2
Gynaecological Oncology
Hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of ovarian cancer
Key Statistics
- 14.2 vs 10.7 mo — OVHIPEC PFS (HIPEC vs CRS)
- 45.7 vs 33.9 mo — OVHIPEC OS (HIPEC vs CRS)
- 100 mg/m² — Cisplatin dose, 40°c, 90 min
Don't-miss facts
-
HIPEC = adjuvant only; surgery to NMRD remains the key determinant of outcome
-
OVHIPEC protocol: cisplatin 100 mg/m² at 40°C for 90 minutes, at interval CRS → PFS 14.2 vs 10.7 mo, OS 45.7 vs 33.9 mo
-
Sodium thiosulphate nephroprotection: 9 g/m² bolus then 12 g/m² over 6 hours before cisplatin
-
HIPEC only proceeds if residual disease ≤2.5 mm after interval CRS; adds ~2 hours theatre time
-
No proven benefit at primary surgery or recurrence – OVHIPEC-2 result awaited (2026)
-
ASA ≤2 required for HIPEC consideration in real-world practice; no significant difference in grade 3/4 complications vs CRS alone
-
NICE IPG688: HIPEC delivery restricted to specialised, trained centres with governance and audit
-
Greatest benefit seen in high-grade serous, HRD/BRCA wild-type tumours
Guideline positions at a glance
NCCN/NICE: HIPEC can be considered at interval CRS, specialised centres ESGO: RCTs only · BGCS: no recommendation
Abbreviation Key
- HIPEC — hyperthermic intraperitoneal chemotherapy
- HRD — homologous recombination deficiency
- IP — intraperitoneal
- BRCA — breast cancer gene
- IV — intravenous
- PARP — poly ADP-ribose polymerase
- CRS — cytoreductive surgery
- NCCN — National Comprehensive Cancer Network
- NMRD — nil macroscopic residual disease
- NICE — National Institute for Health and Care Excellence
- PFS — progression-free survival
- ESGO — European Society of Gynaecological Oncology
- OS — overall survival
- BGCS — British Gynaecological Cancer Society
- RCT — randomised controlled trial EORTC
- QLQ-C30 — European Organisation for Research and Treatment of Cancer core quality-of-life questionnaire
- FIGO — International Federation of Gynecology and Obstetrics
- HRQoL — health-related quality of life
- ASA — American Society of Anaesthesiologists
- MDT — multidisciplinary team
- ERAS — enhanced recovery after surgery
Source: Graham R et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of ovarian cancer. The Obstetrician & Gynaecologist 2024;26:76–83. doi:10.1111/tog.12916
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).